We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bioventix Plc | LSE:BVXP | London | Ordinary Share | GB00B4QVDF07 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -50.00 | -1.12% | 4,425.00 | 4,400.00 | 4,450.00 | 4,475.00 | 4,425.00 | 4,475.00 | 1,798 | 14:55:20 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 12.82M | 8.37M | 1.6071 | 27.53 | 230.51M |
Hot Features
Premium
TIDMBVXP
Bioventix plc
("Bioventix" or the "Company")
Notice of AGM and Posting of Annual Report
Bioventix plc (AIM: BVXP) announces that its Annual General Meeting will be
held at The Winchester Suite, Farnham Castle, Farnham, Surrey, GU9 0AG at 2.00
p.m. on Wednesday 7 December 2016.
Copies of the 2016 Annual Report and the Notice of the Annual General Meeting
have been sent to shareholders and are also available on the Company's website
at www.bioventix.com.
For further information please contact:
Bioventix plc Tel: 01252 728 001
Peter Harrison Chief Executive Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Simon Hicks Corporate Finance
Steve Norcross Corporate Broking
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.
END
(END) Dow Jones Newswires
November 14, 2016 06:47 ET (11:47 GMT)
1 Year Bioventix Chart |
1 Month Bioventix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
